

Radius Health, Inc. Investor Relations Department 950 Winter St, North ?Building 1st Floor North Building 1st Floo Waltham, MA 02451 United States

Visit IR website ☐ Sign-up for Email alerts ☐

# NASDAQ: RDUS Last Trade: 33.72 Trade Time: 3:14 PM ET Apr 19, 2018 Change: -1.39 ♣ (-3.959%) Day Range 33.46 - 34.99 52-Week Range 24.66 - 49.16 Volume 478,357

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

# **Company Profile**

Radius is a sciencedriven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius c... (more)

### **Stock Performance**



## Press Releases [View all]

Mar 30, 2018

Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis

Mar 22, 2018

Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC

Mar 17, 2018

Radius Health Presents Positive Data for the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection at ENDO 2018 Annual Meeting

Mar 12, 2018

Radius Health to Present at ENDO 2018
Including Results of the ACTIVExtend BMD
Responder Analysis for TYMLOS™
(abaloparatide) Injection

Mar 6, 2018

Radius Health to Present at the Cowen 38th Annual Health Care Conference

### Financials [View all]

Fourth Quarter Financial Results

Mar 1, 2018

Annual Report (10-K)

Apr 21, 2017

Proxy Statement (DEF 14A)

Nov 2, 2017

Quarterly Report (10-Q)

Aug 4, 2017

Quarterly Report (10-Q)

May 2, 2017

Quarterly Report (10-Q)